Biotech Bubble Valuations From Sam Islay
April 02, 2015 at 07:13 AM EDT
OrbiMed Advisors managing partner Sam Isaly told CNBC that biotech could be volatile, however, the valuations were ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.